MSInsight, a pioneering startup in precision medicine, has successfully completed a €1.6 million seed funding round led by Calyseed, with participation from Plateau de Saclay Business Angels, Yes Invest, Capital Cell, and banking partners including bpifrance. The investment will accelerate the development of AI-driven diagnostic solutions that leverage DNA sequencing to guide cancer patients toward the most effective therapies.
The company is addressing a major challenge in oncology by developing MSIcare, a software solution designed to optimize the assessment of microsatellite instability (MSI), a key biomarker in cancer diagnosis. By integrating bioinformatics and artificial intelligence, MSIcare enhances diagnostic accuracy, enabling clinicians to make informed treatment decisions with greater confidence. This financing will support the completion of MSIcare’s technological development, validation across various cancer types, and regulatory certification as an in vitro diagnostic medical device.
MSI cancers account for nearly one million new cases annually worldwide, affecting multiple organs, particularly within digestive and gynecological oncology. As a tumor-agnostic biomarker, MSI holds significant therapeutic relevance, with up to 13 million cancer patients globally eligible for diagnostic evaluation each year. Identifying MSI-positive tumors is critical, as these patients can benefit from immunotherapy, transforming treatment outcomes and improving survival rates. However, current diagnostic tools often fail to deliver the precision required, leading to misdiagnosis, inappropriate treatments, and increased healthcare costs.
MSInsight aims to close this gap by harnessing next-generation sequencing (NGS) technology, which has proven highly effective in MSI evaluation. Despite its potential, NGS data interpretation remains complex, with existing algorithms yielding diagnostic errors in up to 30% of cases. MSIcare introduces a new standard by integrating advanced bioinformatics to refine MSI detection, ensuring accurate, scalable, and accessible diagnostics.
Founded in 2022, MSInsight is built on two decades of academic research at the Saint-Antoine Research Center in Paris, led by Scientific Director Professor Alex Duval. The company collaborates closely with global medical institutions to translate research breakthroughs into clinical solutions. Its innovative approach has already been validated in tumor tissue samples, with ongoing development extending to blood-based diagnostics for a less invasive and more accessible option.
CEO and co-founder Arnaud Cutivet emphasized that this funding represents a critical milestone, providing the resources necessary to advance regulatory approvals and expand clinical partnerships. He noted that MSIcare has consistently outperformed existing diagnostic methods and is poised to become the gold standard in MSI assessment.
Calyseed Managing Director Elodie Panier described MSInsight as a key player in the evolution of oncology diagnostics, highlighting the company’s ability to integrate AI-powered bioinformatics seamlessly into laboratory workflows. She emphasized the importance of MSI biomarkers in personalized medicine and noted that MSInsight’s platform is uniquely positioned to meet the growing demand for advanced sequencing-based diagnostics.
Plateau de Saclay Business Angels representative Antoine Risk underscored the startup’s potential to redefine precision medicine by delivering highly accurate genomic analysis that can transform cancer treatment pathways. Capital Cell Director Daniel Oliver praised MSInsight’s vision and confirmed that more than 170 investors contributed to the funding round, recognizing the company’s potential to drive significant advancements in cancer diagnostics.
With this funding, MSInsight strengthens its commitment to equipping healthcare professionals with AI-driven tools that minimize misdiagnosis, enhance therapeutic decision-making, and improve patient outcomes. As the company advances toward regulatory approval, its technology is poised to redefine cancer diagnostics and contribute to a new era of precision medicine.
